A client is being discharged with a cromolyn (Intal) inhaler to assist in the treatment of asthma. The nurse should include which information in the discharge teaching for this medication?
Use this inhaler 15 minutes prior to physical activity
Tachycardia is an adverse effect associated with this medication
This medication should not be discontinued abruptly.
Injections are required weekly to properly prevent asthma attacks.
The Correct Answer is A
A. Use this inhaler 15 minutes prior to physical activity: This is the correct recommendation for cromolyn. It is a mast cell stabilizer that helps prevent asthma symptoms by inhibiting the release of inflammatory mediators. Using it before physical activity can help minimize exercise-induced bronchospasm.
B. Tachycardia is an adverse effect associated with this medication: This statement is misleading. Cromolyn is not typically associated with tachycardia as an adverse effect. Unlike bronchodilators, which can cause increased heart rate, cromolyn primarily works to stabilize mast cells and has a different side effect profile.
C. This medication should not be discontinued abruptly: While it is generally good practice to consult a healthcare provider before stopping any asthma medication, cromolyn does not have a significant risk of withdrawal symptoms like corticosteroids might. It is more important to maintain regular use for effectiveness rather than fear abrupt discontinuation.
D. Injections are required weekly to properly prevent asthma attacks: This statement is incorrect. Cromolyn is administered via inhalation, not by injection, and does not require weekly injections. Patients should use the inhaler as prescribed, typically several times a day, depending on their individual treatment plan.
Free Nursing Test Bank
- Free Pharmacology Quiz 1
- Free Medical-Surgical Quiz 2
- Free Fundamentals Quiz 3
- Free Maternal-Newborn Quiz 4
- Free Anatomy and Physiology Quiz 5
- Free Obstetrics and Pediatrics Quiz 6
- Free Fluid and Electrolytes Quiz 7
- Free Community Health Quiz 8
- Free Promoting Health across the Lifespan Quiz 9
- Free Multidimensional Care Quiz 10
View Related questions
Correct Answer is C
Explanation
A) Montelukast (Singulair): This medication is a leukotriene receptor antagonist used to manage asthma and allergic rhinitis. It does not contain soy or soy-derived ingredients, making it a safe option for a client with a soybean allergy. There are no known contraindications related to soy in this medication.
B) Methylprednisolone (Solumedrol): This is a corticosteroid used to reduce inflammation. It is not contraindicated for clients with a soybean allergy, as it does not contain soy-derived components. The medication primarily poses risks related to long-term use, but not specifically regarding soybean allergies.
C) Ipratropium bromide (Atrovent): This medication is an anticholinergic used to relieve bronchospasm. Ipratropium bromide is formulated with soy lecithin, which is derived from soybeans. Therefore, it is contraindicated for clients with a known allergy to soybeans, as it may trigger an allergic reaction.
D) Albuterol (Ventolin): This medication is a short-acting beta-agonist used for quick relief of bronchospasm. It does not contain any soy components and is generally safe for patients with soybean allergies. While there may be other considerations for its use, the allergy to soy is not a concern with this medication.
Correct Answer is A
Explanation
A. This medication is for long-term treatment for asthma: This statement indicates an accurate understanding of montelukast. It is a leukotriene receptor antagonist used for long-term control and management of asthma symptoms and to prevent exercise-induced bronchoconstriction.
B. This medication has a tendency to produce anaphylaxis: This statement is incorrect. While allergic reactions can occur with montelukast, it is not commonly associated with anaphylaxis. Clients should be aware of potential side effects, but anaphylaxis is not a common risk.
C. I can repeat this medication twice prior to seeking medical attention: This statement is misleading. Montelukast is taken once daily for asthma management, and it is not meant to be repeated or used as a rescue medication in acute situations. Clients should seek medical attention for worsening symptoms instead of relying on repeating doses.
D. Bloodwork is required regularly to monitor the therapeutic levels of this medication: This statement is incorrect. Montelukast does not require routine blood monitoring for therapeutic levels, unlike some other medications used for asthma management. It is generally well-tolerated without the need for regular blood tests.